


PHARMACEUTICAL 2020



Verastem Inc. Rank 276 of 362







PHARMACEUTICAL 2020



Verastem Inc. Rank 276 of 362

The relative strengths and weaknesses of Verastem Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verastem Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 86% points. The greatest weakness of Verastem Inc. is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 150% points.

The company's Economic Capital Ratio, given in the ranking table, is -423%, being 120% points below the market average of -303%.

Input Variable	Value in 1000 USD
Assets, Current	84,961
Cost of Goods Sold	0
Intangible Assets	20,008
Liabilities, Current	29,890
Liabilities, Non-Current	4,359
Other Assets	39,130
Other Compr. Net Income	-113
Other Expenses	23,415
Other Liabilities	103,623
Other Net Income	3,740
Property and Equipment	947
Research and Development	45,778
Revenues	17,456
Selling, General and Administrative Expense	101,212

Output Variable	Value in 1000 USD
Assets	145,046
Liabilities	137,872
Expenses	170,405
Stockholders Equity	7,174
Net Income	-149,209
Comprehensive Net Income	-149,266
Economic Capital Ratio	-423%

